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Abstract: Vascular dementia is a common condition for which there are no effective approved 
pharmacological treatments available. Absence of effective treatments creates a difﬁ  cult situa-
tion for those suffering from the disease, their caregivers, and healthcare providers. This review 
will address our current understanding of the mechanisms of nerve cell damage due to ischemia 
and summarize available clinical trial data on several commonly used compounds including 
memantine, donepezil, galantamine, rivastigmine, nimodipine, hydergine, nicergoline, CDP-
choline, folic acid, as well as such nonpharmacological approaches as validation therapy.
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Introduction
Vascular dementia is a common condition. It has been estimated that 1 to 4 out of 100 
individuals aged 65 years will develop it (Malouf and Birks 2004). The prevalence 
increases to 14–16 out of 100 individuals over 80 years old (Román 2002). Many 
individuals with vascular dementia will require institutionalization. Despite all of the 
recent investment in experimental and clinical neuroscience, there are no effective 
pharmacological compounds approved for treatment of vascular dementia in any 
jurisdiction worldwide. Such absence of effective treatments for a rather common 
disorder is uncommon in medicine and creates a difﬁ  cult situation for those suffering 
from the disease, their caregivers and healthcare providers. For example, a number 
of studies have linked vascular dementia to mood disorders, particularly depression 
(Groves 1999; Lyketsos 2000) and greater caregiver burden was found among those 
caring for vascular dementia when compared with those caring for Alzheimer’s disease 
(Vetter 1999; Annerstedt 2000). Urgent efforts are needed to address this knowledge 
vacuum. This review will discuss our current understanding of the mechanisms of nerve 
cell damage due to ischemia and will brieﬂ  y summarize available vascular dementia 
treatment clinical trial data.
Clinical deﬁ  nitions and epidemiology
Vascular dementia represents a clinical syndrome that includes a wide spectrum of 
cognitive dysfunctions resulting from brain tissue death due to ischemia caused by 
vascular disease. A number of excellent reviews have been written on the topics of its 
diagnosis, pathogenesis, and epidemiology (Román 2002; Wallin 2003; Micieli 2006). 
It is believed that vascular dementia is a distinct clinical and pathological entity from 
Alzheimer’s dementia, Lewy body dementia, or fronto-temporal dementia, although 
elements of vascular disease may be present in all of these conditions. Treatment of 
vascular dementia has also received extensive coverage (Broich 2003; Malouf and 
Birks 2004; Pantoni 2004; Schindler 2005). The prevailing conclusion of these reports 
is that most vascular dementia trials have produced disappointing results. It is important Clinical Interventions in Aging 2007:2(3) 328
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to note that so far no drug has been approved by regulatory 
agencies to treat vascular dementia (Pantoni 2004). Epide-
miologically, vascular dementia is considered the second 
most prevalent type of dementia after Alzheimer’s disease 
although this point of view maybe brought to doubt by our 
increasing understanding of Lewy body disease (Zesiewicz 
et al 2001; Henriksen et al 2006). From a clinician’s point 
of view, vascular dementia represents a major source of 
frustration because of its relatively high prevalence and lack 
of effective treatment options.
Mechanisms of neurodegeneration 
and the role of glutamate receptors
Vascular dementia (VaD) arises as a consequence of ischemic 
insults such as hemorrhage and hypoperfusion that trigger 
neurodegeneration by depriving nerve cells of oxygen and 
glucose (Kalaria 2003; Francis 2006). Oxygen and glucose 
deprivation results in depletion of nerve cell energy supplies, 
leading to membrane depolarization, followed by an exces-
sive release of glutamate, which, in turn, over activates the 
N-methyl-D-aspartate (NMDA) receptor/channel complex 
(NMDAR). Over activation of neuronal NMDA receptors 
allows inﬂ  ux of toxic levels of Ca2+ into nerve cells (Choi 
and Rothman 1990; Coyle and Puttfarken 1993), which 
enables activation of various intracellular calcium-dependent 
enzymes (see Baskys and Blaabjerg, 2005 for review and 
refs. therein). The mechanism of glutamate toxicity and its 
various components are potential therapeutic targets, and 
merit a more detailed discussion here.
L-glutamate is a high afﬁ  nity agonist on at least 4 major 
subtypes of neuronal glutamate receptors. Olney initially 
described glutamate toxicity in 1969 when he found that 
treatment of mice with monosodium glutamate caused brain 
lesions (Olney 1969). Three of these subtypes, named accord-
ing to their preferred agonists kainate, AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA, 
implicated in cell death, are classiﬁ  ed as ionotropic glutamate 
receptors (iGluRs), being directly linked to neuronal ion 
channels. It is generally believed that excessive stimulation 
of ionotropic glutamate receptors triggers an inﬂ  ux of Na+ 
and Ca2+ through the receptor-controlled channels and sub-
sequently leads to cell death. It has been proposed that Ca2+ 
entering through NMDA receptors may be especially lethal 
due to co-localization of these channels with particularly 
sensitive intracellular targets (eg, calpain-induced cytoskel-
etal breakdown, phospholipase-A2-induced formation of 
arachidonic acid and its metabolites, membrane translocation 
of protein kinase C, Ca2+-activated endonuclease destruction 
of cellular DNA, and other Ca2+-dependent processes). For 
more details on the glutamate toxicity, the reader can be 
referred to several excellent reviews have been published 
on this topic (Portera-Cailliau et al 1997; Budd et al 1998; 
Martin et al 1998) recognizing the critical role of NMDA 
receptors in the pathophysiology of ischemic nerve cell death. 
The nature of cell death (necrosis vs. apoptosis) remains a 
subject of debate (as perhaps is the deﬁ  nition of the term 
“apoptosis” (eg, see Sloviter 2002). Morphological and other 
features of both apoptotic and necrotic cell death have been 
reported following ischemic damage (Nitatori 1995; Endres 
1998; Francis 2006).
Based on this scenario it is not surprising that the focus 
in treating ischemic brain damage has been on designing 
drugs that are iGluR antagonists, in particular NMDAR 
antagonists (such as phencyclidine, ketamine or MK-801), 
and thereby inhibit the increase in intracellular Ca2+. In 
animal models, these drugs have proved to be very effective 
against ischemic nerve cell injury, but in the human clini-
cal trials the results have been disappointing, mainly due 
to severe side effects such as psychosis, nausea, vomiting, 
impaired memory and in some cases even cell death (Muir 
and Lees 1995). There have been numerous attempts to 
develop drugs that prevent ischemic brain tissue death, most 
of them unsuccessful. For example, out of 178 controlled 
clinical trials of acute stroke therapies reported in English 
language literature in the 20th century only four produced 
positive results. Among them, clot-dissolving treatments 
were more likely to be successful. In contrast, out of 49 
neuroprotective drugs tested in 114 stroke studies none was 
successful (Gladstone 2002). The numerous reasons for this 
failure range from clinical trial design issues to failure to 
fully appreciate the complexity of regulations controlling 
nerve cell death and survival, and have received an excel-
lent discussion elsewhere (Gladstone 2002).
Methods
An extensive search of Medline and the Cochrane database 
yielded slightly over twenty studies pertinent to this review. 
A wealth of information was found regarding treatment for 
Alzheimer’s dementia, mixed dementia, and other types of 
cognitive impairment, but an attempt was made to focus 
exclusively on vascular dementia studies. Due to changing 
concepts of this disease over time, some older studies used 
diagnostic criteria different from current deﬁ  nitions. Efforts 
were made to use data appropriate to the current diagnostic 
deﬁ  nition of vascular dementia. In addition, some thera-
pies (eg, folic acid, CDP-choline, validation therapy) were Clinical Interventions in Aging 2007:2(3) 329
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included in this review due to their possible relevance to the 
treatment of vascular dementia, despite the lack of clinical 
trials speciﬁ  cally addressing the condition. A summary table 
was also prepared featuring results of selected trials focusing, 
again, on vascular dementia (Table 1).
Vascular dementia clinical trials
Memantine
Memantine belongs to the aminoadamantane chemical class 
and is structurally similar to amantadine, an antiparkinson 
and antiviral drug. It was initially developed to treat Parkin-
son’s disease and was ﬁ  rst tested in Europe in the 1990s, and 
later in the US, as a neuroprotective compound. In addition 
to its propensity to release dopamine from dopaminergic ter-
minals, memantine is a weak, noncompetitive, open channel 
(use-dependent) antagonist of the glutamate NMDA receptor 
(Lipton 2004). Since NMDA receptor-mediated excitotoxic 
nerve cell death is considered of paramount importance in 
ischemic nerve cell damage, NMDA antagonist properties 
make memantine an attractive neuroprotective compound. 
On the other hand, NMDA receptor antagonists have been 
well known to cause hallucinations and impair cognition, 
attributes which have seriously hampered their clinical 
development.
Memantine has been tested in two studies that included 
815 subjects with mild to moderately advanced vascular 
dementia (Areosa et al 2005, see Table 1). Treatment with 
20 mg/day dose or placebo lasted 28 weeks. Data analysis 
showed a signiﬁ  cant improvement in cognitive function, 
measured as ADAS-cog (Alzheimer’s Disease Assessment 
Scale-cognitive subscale), from baseline, over placebo. 
There was no change in the CGI (Clinical Global Impres-
sion scale), CGIC (Clinical Global Impression of Change), 
or the NOSGER (Nurses Observational Scale for Geriatric 
Patients) self-care subscale. A small but statistically sig-
niﬁ  cant improvement was found on NOSGER disturbing 
behavior scale. In a study on a mixed patient population 
including Alzheimer’s, vascular, and mixed dementia 
patients (n = 168), there was no signiﬁ  cant effect on ADLs 
(Activities of Daily Living), but there was a signiﬁ  cant 
positive effect on CGIC (Areosa 2005). No differences 
between memantine and placebo groups were found in 
dropout rates or the number of those suffering at least one 
adverse event, suggesting that the drug is well tolerated. 
Similar ﬁ  ndings indicating an improvement in cognition 
and global function emerged from several smaller studies 
(n = 59–88) involving patients with unspeciﬁ  ed dementia 
(Areosa 2005).
It appears from the above ﬁ  ndings that memantine, an 
NMDA receptor antagonist, has a positive effect on cogni-
tion in patients with vascular dementia. This conclusion is 
in a very sharp contrast to the classical understanding of 
the NMDA receptor role in memory and learning (eg, see 
MacDonald et al 1996) and is difﬁ  cult to explain. Lipton and 
Chen (2004) and Lipton (2004) proposed that memantine, 
which is an open channel (or use-dependent) antagonist 
of NMDA receptor channel, inhibits “elevated” NMDAR 
channel activity while leaving “normal” activity intact. This 
theory does not adequately address the fact that the clinical 
efﬁ  cacy of memantine is signiﬁ  cantly more pronounced in 
advanced dementia but not in early dementia where excessive 
NMDA receptor channel/activation would be the greatest. 
On the other hand, closed NMDA receptor channels do not 
appear to have any activity and it remains to be seen whether 
the proposed model is valid or memantine’s clinical efﬁ  cacy 
in dementia is mediated by a mechanism other than NMDAR 
channel blockade.
Galantamine
Galantamine is a cholinesterase inhibitor and n-cholino 
receptor modulator with documented efﬁ  cacy in treat-
ment of Alzheimer’s disease symptoms. Two large studies 
involving vascular dementia patients were analyzed (Craig 
and Birks 2006). One included vascular dementia patients 
and Alzheimer’s patients showing radiological and his-
torical evidence of cerebrovascular disease. Analysis of 
the vascular subgroup showed that a galantamine effect 
on ADAS-cog did not reach statistical signiﬁ  cance in 
comparison to placebo (p = 0.06). Analysis of all patients 
(combined vascular dementia and Alzheimer’s with signs 
of cerebrovascular disease) showed a signiﬁ  cant treatment 
effect on a variety of measures including ADAS-cog, 
CIBIC+ (Clinician’s Interview-based Impression of Change 
plus caregiver input), NPI (Neuropsychiatric Inventory) and 
DAD (Disability Assessment for Dementia). There was a 
signiﬁ  cant number of adverse effects in both analyses, 
which is in keeping with galantamine acetylcholinesterase 
inhibiting properties.
The second study that was analyzed included 786 subjects 
with vascular dementia (Craig and Birks 2006, see Table 1). 
One major change following 26-week galantamine treatment 
was in the ADAS-cog outcome measure. There was no 
difference in activities of daily living, global (CIBIC+) or 
behavioral (NPI) scales. Interestingly, there was a signiﬁ  cant 
improvement in executive function. A similar improvement 
in executive function was also reported in a small double Clinical Interventions in Aging 2007:2(3) 330
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Table 1 Summary of published meta-analysis data of vascular dementia treatment clinical trials
Treatment Number  of  studies Subjects Duration Beneﬁ  t  Side effects  References
Memantine  2 studies  815  28 weeks  Improvement:  No difference in  Areosa et al 2005 
  Mild to moderate      Cognition (ADAS-cog)  those who had at  Orgogozo et al 2002 
  VaD      Behavior (NOSGER disturbing  least one adverse  Wilcock et al 2002 
       behavior  scale)  event
       No  change:   
        Global rating (CGI, CIBIC-plus,   
       CGIC)   
        ADLs (NOSGER self-care)   
Galantamine  1 study  449–543  24 weeks  Improvement:  Higher rates of  Craig and Birks 2006 
  VaD + AD with      Cognition (ADAS-cog)  withdrawals,  Bullock et al 2004 
  cerebrovascular      Global rating (CIBIC-plus)  withdrawals due to 
  disease      Behavior (NPI)  adverse event, 
        ADLs (ADCS-ADL)  total number of 
          patients with at 
          least one adverse 
          event, and rates of 
         nausea/vomiting. 
          No difference in 
          number of deaths 
  1 study  786  26 weeks  Improvement:  Higher rates of  (GAL-INT-26, 2004 
  VaD      Cognition (ADAS-cog)  withdrawals due to  unpublished data) 
        Functional ability (DAD)  adverse events 
       No  change:   
        Global rating (CIBIC-plus)   
       Behavior  (NPI)   
        ADLs (ADCS-ADL)  No difference in 
         incidence  of 
          adverse events or
          deaths through 30 
         days  post-trial.
Donepezil  2 studies  1,219  12 weeks  Improvement:  Signiﬁ  cant  Malouf and Birks 2005 
  VaD    and 24  Cognition (ADAS-cog, MMSE)  increase in one 
      weeks  Global rating (CIBIC-plus,  side effect or 
       CDR-SB)  more
        ADLs (IADLs, ADFACS)  No serious adverse 
         effects 
Rivastigmine  1 study  16  22 months  Improved:    Moretti et al 2002 
  VaD      Executive function (Ten point   
       clock  drawing)   
       Behavior  (NPI)   
Hydergine  2 studies  78  6 and 12  No change:  Not addressed  Olin et al 2002 and 
 VaD    weeks  Global  rating    refs.  therein 
  11 studies  617  60 days to  Improvement:  No signiﬁ  cant  Olin et al 2002 and 
  Various dementias    12 months  Global rating  difference in at  refs. therein 
        Comprehensive rating  least one adverse 
         effect 
Nicergoline  1 study  50  2 months  Improved:    Fioravanti and Flicker 
  Multi-infarct      Global rating (CGI)    2001, Saletu et al 
 dementia         1995 
          
          
  1 study  139  6 months  Improved:    Herrmann et al 1997 
 Multi-infarct      Memory  (MMSE)   
  dementia      Global rating (CGI)   
  1 study  101  12 months  Improved:  No signiﬁ  cant  Fioravanti and Flicker 
  Alzheimer’s      Memory (MMSE)  difference in at  2001 and refs. therein 
  dementia + Multi-      Global rating (CGI)  least one adverse 
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Table 1 (Continued) 
Treatment Number  of  studies Subjects Duration Beneﬁ  t  Side effects  References
  infarct dementia      Behavior (SCAG)  event during or by 
          end of treatment
Nimodipine  3 studies  200  12 weeks  Improvement:    Lopez-Arieta and
 VaD      SCAG  (n = 130)    Birks 2002 and
       Cognition  (n = 200)   refs.  therein
        Global function (n = 62)  
       No  change:   
  2 studies  274  24 weeks  ADLs (n = 65)  
 VaD      No  change:   
       Cognition  (n = 274)  
        Global function (n = 209)  
        Severity of disease (n = 209)  
       ADLs  (n = 274)  
Abbreviations: AD, Alzheimer’s disease; VaD, vascular dementia.
blind study of 22 male patients with minimal cognitive 
impairment (MCI) (Koontz and Baskys 2005). This study 
used a sophisticated computer technology to capture the 
change and also reported a modest but statistically signiﬁ  -
cant improvement in working memory. Unfortunately, no 
data were available comparing working memory scores in 
the vascular dementia study, although such difference is not 
unlikely in light of the ADAS-cog change. In summary, it 
appears that although galantamine seems to improve work-
ing memory in vascular dementia patients, it does not have 
a clearly documented clinical beneﬁ  t in vascular dementia. 
The presence of side effects suggests that caution should be 
exercised in prescribing this compound to patients with pure 
vascular dementia.
Donepezil
Two large-scale randomized clinical studies enrolled 
1219 patients with probable or possible vascular cogni-
tive impairment diagnosed according to NINCDS-AIREN 
(National Institute of Neurological Disorders and Stroke 
and the Association International pour la Recherche et l’ 
Enseignement en Neurosciences) criteria for a 24-week 
donepezil treatment (Malouf and Birks 2004; Roman et al 
2005, see Table 1). Comparison of donepezil with placebo 
showed that donepezil had a beneﬁ  cial effect on cognitive 
function, global assessment, and activities of daily living. 
Side effects were more pronounced in the donepezil group. 
Both ﬁ  ve and ten milligram a day doses were shown to be 
effective for most, but not all measures. CDR (Clinical 
Dementia Rating) and activity of daily living ratings, did not 
improve at 5 mg dose but there was a signiﬁ  cant improve-
ment at 10 mg dose. CIBIC+ (Clinician’s Interview-Based 
Impression of Change-plus scale) showed improved global 
function among participants taking 5 mg of donepezil daily 
compared with the placebo group but this was not seen in 
the 10 mg/day dose group. The study did not entirely rule 
out the possibility that a proportion of patients enrolled into 
this study had Alzheimer’s dementia rather than vascular 
dementia, and that the beneﬁ  cial effect of the drug was 
due to its activity associated with the Alzheimer’s disease 
pathology (Malouf and Birks 2004) rather than with the 
pathological changes underlying vascular dementia. Since 
many patients also suffered from co-morbid conditions 
such as cardiovascular disease, it was impossible to rule out 
potentially possible drug–drug interactions between done-
pezil and the compounds used to treat cardiac or vascular 
conditions in these patients.
Rivastigmine
Rivastigmine is a nonspeciﬁ  c inhibitor of two enzymes: 
acetylcholinesterase (AChE) and butyrylcholinesterase 
(BuChE). Rivastigmine’s efﬁ  cacy in in vascular dementia 
has been studied insufﬁ  ciently to draw any meaningful 
conclusions. One study conducted on 16 patients with 
vascular dementia showed some beneﬁ  ts of rivastigmine 
on executive function and behavior (Moretti 2002; Vincent 
and Lane 2003). More studies are needed to understand 
if rivastigmine could be used for treatment of vascular 
dementia.
Hydergine
Hydergine is a combination of four dihydro-derivatives of 
ergotoxine, also referred to as ergoloid mesylates, and has 
been in use in clinical medicine since 1949 for treatment of 
a variety of conditions. Currently it is being used for treating 
patients with either dementia or “age-related” cognitive Clinical Interventions in Aging 2007:2(3) 332
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symptoms and has been approved by US Food and Drug 
Administration (FDA) for treatment of “idiopatic decline 
in mental capacity” (Olin et al 2006). Cochrane database 
search revealed meta-analysis results of 11 hydergine 
clinical trials on over 200 patients with diagnoses that 
included Alzheimer’s disease, vascular dementia, cerebral 
insufﬁ  ciency and thrombembolic stroke. The combined 
analyses indicated that hydergine had statistically signiﬁ  cant 
beneﬁ  ts on global measures in an apparent dose-dependent 
manner (see Table 1). However, greater effects were seen 
at doses higher than those currently approved by US FDA 
(4.5 mg/day). The only two studies speciﬁ  cally looking 
at vascular dementia were quite small (n = 54, see Table 1) 
and analysis was limited because of the absence of compa-
rable rating scales. Global rating changes were analyzed 
however, and found to be not statistically signiﬁ  cant. Based 
on these analyses, clinical trial of hydergine at higher doses 
as well as more comprehensive investigations into its role 
in vascular dementia are needed to determine its potential 
clinical beneﬁ  t.
Nicergoline
Nicergoline (8-beta-(bromonicotinoylhydroxymethyl)-
1,6-dimethyl-10alpha-metoxyergoline) is another ergot 
derivative that has been in clinical use in over 50 countries 
for over three decades for treatment of cognitive, affective 
and behavioral disorders in older people. It has a multitude 
of effects that include actions on neurotransmitters such as 
acetylcholine, noradrenaline and dopamine, and intracel-
lular signaling cascades. The Cochrane database provides 
meta-analysis data from 11 nicergoline clinical trials with 
approximately 1300 patients, half of who received nicer-
goline and the other half placebo (Fioravanti and Flicker 
2004). Diagnoses of these trial patients varied, including 
“senile cognitive deterioration,” “cerebral metabolic and 
nutritional disturbances”, “hypertension and leukoaraiosis”, 
“senile cerebral insufﬁ  ciency”, “senile dementia” and “senile 
dementia of Alzheimer’s type”. Two studies speciﬁ  cally 
dealt with patients diagnosed with “multi-infarct dementia” 
and another study focused on a population with multi-infarct 
dementia and Alzheimer’s type dementia (see Table 1).
Review of one mixed-group meta-analysis data revealed 
that there was a signiﬁ  cant effect of nicergoline on MMSE 
scores in 261 patients from three studies ranging in dura-
tion from 3 to 12 months. The effect size obtained by using 
weighted mean difference and ﬁ  xed effect model was 2.32 
(95% CI 1.32–3.32) and was statistically signiﬁ  cant. Two 
of the studies included patients with multi-infarct dementia. 
No ADAS-cog data were found for patients other than those 
with the diagnosis of Alzheimer’s disease. On the CGI 
scale, mixed-group meta-analysis yielded a Peto odds ratio 
of 3.33 (95% CI 2.50–4.43) for improvement in subjects 
taking nicergoline as opposed to subjects taking placebo. 
Each of the three studies featuring patients with multi-infarct 
dementia also showed global improvement. Finally, for the 
mixed-group, there was a modest (Peto odds ratio 1.51) 
but statistically signiﬁ  cant increase of adverse effects with 
nicergoline.
In summary, it appears that nicergoline may have a ben-
eﬁ  cial effect in vascular dementia but further studies with 
patients diagnosed using modern day diagnostic criteria are 
needed to conﬁ  rm these ﬁ  ndings. There are no data on the 
effects of the combination of acetylcholinesterase inhibitors 
or memantine with nicergoline in patients with vascular 
dementia.
Nimodipine
Nimodipine is an L-type voltage-dependent Ca2+ channel 
antagonist with antihypertensive properties. Excessive 
opening of voltage-dependent Ca2+ channels could accom-
pany NMDA receptor-induced membrane depolarization 
and contribute to toxicity mediated by already large Ca2+ 
inﬂ  ux through NMDA receptor controlled ion channels. 
Therefore, blockade of these channels by nipodipine, could, 
at least in theory, lead to reduction of ischemic nerve cell 
death. Antihypertensive properties of Ca2+ channel blockade 
could further mitigate nerve cell damage in vascular demen-
tia by eliminating an important risk factor (although blood 
pressure reduction did not substantially alter the course of 
vascular dementia, see below and Table 1). Review of the 
Cochrane database revealed meta-analysis data from 4 trials 
of nimodipine (90 mg/day at 12 and 24 weeks) in 409 patients 
with vascular dementia (Lopez-Arrieta and Birks 2005). 
These results were, unlike data with Alzheimer’s disease 
patients (presented in the same report by Lopez-Arieta and 
Birks 2005), disappointing. While there was evidence for sta-
tistically signiﬁ  cant improvement of SCAG (Sandoz Clinical 
Assessment Geriatric) scores, global function, and cognitive 
function at 12 weeks, there was no statistically signiﬁ  cant 
improvement in global function, cognitive scores, or CGI 
disease severity scores at 24 weeks. No improvement was 
seen in ADLs. These studies suggest that voltage-dependent 
Ca2+ channels play a limited, if any, role in pathogenesis of 
vascular dementia related symptoms and voltage-dependent 
Ca2+ channel antagonists such as nimodipine are not likely 
to be useful in their treatment.Clinical Interventions in Aging 2007:2(3) 333
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Blood pressure-lowering therapies
It is an interesting question, both scientiﬁ  cally and clinically, 
whether eliminating one of the recognized risk factors for 
vascular dementia – elevated blood pressure—will reduce 
the incidence of vascular dementia. Three randomized, 
placebo-controlled studies involving over 12,000 patients 
with elevated blood pressure but no cognitive impairment 
examined whether lowering blood pressure would reduce 
the incidence of vascular dementia. Analysis of these studies 
revealed no convincing evidence that lowering blood pressure 
prevented development of cognitive impairment including 
vascular dementia (McGuinness et al 2006). Although quite 
convincing, these studies were not perfect in that the con-
trol group patients’ blood pressures often exceeded preset 
allowable values, necessitating that the patients would have 
to receive antihypertensives.
CDP-choline
This compound is commonly used in European countries for 
treatment of cognitive disorders when their basis is thought to 
be vascular pathology. In ischemic conditions, CDP-choline 
(cytidine-5′-diphosphate choline; citicoline) is thought to act 
by blocking cell membrane degradation and release of toxic 
arachidonic acid and perhaps other harmful components of 
this process. It easily crosses blood-brain barrier. It is avail-
able as over-the-counter dietary supplement in the US and 
requires no prescription. There have been numerous studies 
of CDP-choline in various types of subjects, however, these 
studies vary signiﬁ  cantly in their duration, subject selection, 
geography and outcome measures. Cochrane database is 
the source of several studies that included subjects whose 
complaints or diagnoses ranged from subjective memory 
complaints to moderately advanced vascular dementia 
(Fioravanti and Yanagi 2005). Available meta-analysis data 
indicate that treatment with CDP-choline results in a mod-
est but statistically signiﬁ  cant improvement in memory, 
behavior and global function (Fioravanti and Yanagi 2005). 
Clearly, additional studies with more uniform patient selec-
tion, accepted diagnostic criteria and outcome measures are 
needed to further understand CDP-choline beneﬁ  ts.
Folic acid
Folic acid is a vitamin which plays a key role in central 
nervous system development. Folic acid deﬁ  ciency is associ-
ated with high homocysteine levels, which has been linked 
to an array of neuropsychiatric disorders, including depres-
sion and dementia and there has been much thought paid to 
the use of folic acid in improving cognitive function in the 
elderly, especially in the case of dementia (Reynolds 2002). 
The Cochrane database provided meta-analysis data of four 
double-blind controlled trials with participants ranging from 
the healthy and cognitively intact, to mild-moderate cognitive 
decline, and to dementia (Malouf et al 2003). No beneﬁ  t was 
found for improving cognition, though the trials were short 
(35 days to 3 months) and no speciﬁ  c subgroups of cognitive 
decline were studied. Further investigations with longer trials 
and focused examination of disease states such as vascular 
dementia may help to delineate the presumed beneﬁ  ts of folic 
acid in vascular dementia.
Validation therapy
Validation therapy is a collection of nonpharmacologic 
techniques described by Naomi Feil (1992) to treat disorien-
tation and confusion in demented individuals. Empathy and 
consideration of emotional states are emphasized in relating 
to these patients. The therapy was examined for this review 
because of the recent attention paid to its legitimacy and 
efﬁ  cacy. The Cochrane database revealed meta-analysis data 
from 3 small randomized trials of patients with dementia. 
There were no signiﬁ  cant effects in terms of cognitive or 
behavioral beneﬁ  t. However, one study did show behavioral 
improvements with validation versus placebo (see Table 1) 
and another found some beneﬁ  t for depression with validation 
versus social contact (Neal and Wright 2006). Because of the 
low power of these studies, future investigations regarding 
the validation therapy may be useful in determining whether 
these positive results may be expanded upon.
Conclusions and future directions
From the studies reviewed here, one may draw several con-
clusions. First, there are relatively few studies on vascular 
dementia treatment and no compound has been approved 
by any regulatory body for treatment of vascular dementia. 
Second, it appears that there are several compounds with 
different mechanisms of action that show mild efﬁ  cacy in 
improving cognition and even ADLs in patients with vascular 
dementia. Third, there is one compound (memantine) that 
has been suggested to act within the conﬁ  nes of the current 
excitotoxic cell death model, although direct evidence con-
ﬁ  rming this hypothesis is still lacking. Overall, one could 
easily conclude that a number of different mechanisms may 
be at play in ethiopathogenesis of vascular dementia. Vascu-
lar conditions aside, nerve cell resistance to injury and our 
efforts to manipulate it still remains a conundrum, which will 
require new technologies to solve. One technology that might 
be particularly useful in this regard is microarray analysis of Clinical Interventions in Aging 2007:2(3) 334
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messenger mRNA. Microarray analysis allows simultaneous 
monitoring of the behavior of a very large number of genes, 
up to the whole genome. Studies using microarray analysis 
reveal a very complex picture associated with the regulation 
of nerve cell susceptibility to injury (or other diseases such as 
cancer). For example, in a recent study of mechanisms that 
might be responsible for glutamate metabotropic receptor 
mediated neuroprotection against NMDA toxicity, cDNA 
microarray analysis of 1128 brain-relevant genes revealed 
that the neuroprotection was associated with simultaneous 
activation of endocytosis, and inactivation of inﬂ  ammation, 
cell adhesion, apoptotic cell death, and transcription-related 
genes (Baskys and Blaabjerg 2005). This ﬁ  nding suggests 
that future neuroprotective drugs expected to be effective 
in treatment of vascular dementia will have to be directed 
simultaneously at multiple targets. Their components will 
have to be able to suppress inﬂ  ammation, cell adhesion, 
apoptotic cell death and certain transcription-related genes 
to the extent that a pre-disease state could be achieved.
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